Research shows DHL-11 significantly suppresses tumor growth in breast cancer organoids — Evidence Review
Published in Acta Pharmaceutica Sinica B
Researched by
— the AI search engine for science
Table of Contents
A newly identified plant compound, DHL-11, inhibits aggressive triple-negative breast cancer cell growth and metastasis by degrading a key cancer enzyme through an unconventional mechanism. Related research broadly supports the potential of plant-derived compounds in cancer therapy, including their ability to target molecular pathways and suppress tumor progression, as shown in studies reviewed by the study organization.
- Multiple related studies have found that plant-derived compounds can modulate critical cancer-associated pathways, such as JAK/STAT and cell cycle regulators, and promote apoptosis, supporting DHL-11’s multi-targeted approach 1 2 3 4 5.
- Evidence suggests phytochemicals not only inhibit tumor growth but may also suppress metastasis and improve therapeutic outcomes, aligning with DHL-11’s observed effects on both primary tumor growth and metastasis in animal models 3 6 7 8 9 10.
- Challenges identified in related research—including issues of bioavailability and the need for translation from preclinical to clinical settings—highlight areas for further investigation, which the DHL-11 study addresses by demonstrating efficacy in patient-derived organoids and animal models 3 5.
Study Overview and Key Findings
Triple-negative breast cancer (TNBC) remains one of the most difficult-to-treat subtypes, lacking effective targeted therapies and often resulting in poor outcomes. This study investigates DHL-11, a newly discovered limonoid from the plant Munronia henryi, for its ability to inhibit TNBC by targeting the enzyme IMPDH2 in a novel way. Unlike many compounds that block enzyme active sites, DHL-11 degrades IMPDH2 by binding to a non-catalytic site, disrupting key protein interactions, and triggering a cascade leading to cancer cell death.
| Property | Value |
|---|---|
| Study Year | 2025 |
| Journal Name | Acta Pharmaceutica Sinica B |
| Authors | Yu Zhu, Zhibi Zhang, Xueqin Dai, Wenjing Liu, Jian Sun, Jialing Liu, Yuxin Zhao, Wenlong Ren, Chenglong Pan, Zhongmei Zhou, Ying Yan, Longlong Zhang, Ceshi Chen |
| Population | Breast cancer patient-derived organoids |
| Methods | Animal Study |
| Outcome | Cancer cell growth, migration, apoptosis, and DNA damage |
| Results | DHL-11 significantly suppressed tumor growth and metastasis |
Literature Review: Related Studies
To contextualize the findings on DHL-11, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used to identify relevant studies:
- DHL-11 breast cancer cell effects
- plant compound tumor growth suppression
- metastasis inhibition aggressive cancer treatments
Below, we summarize the literature under key topics related to plant-derived compounds in cancer therapy.
| Topic | Key Findings |
|---|---|
| How do plant-derived compounds affect cancer growth and cell death? | - Phytochemicals can suppress tumor growth by targeting oncogenic signaling pathways and promoting apoptosis 1 2 3 4 5. - Compounds like EGCG, curcumin, and quercetin modulate gene expression, including miRNAs, to induce cancer cell death and inhibit proliferation 2 4. |
| Can plant-derived compounds inhibit metastasis and tumor progression? | - Plant-based therapies have demonstrated efficacy in reducing metastasis and tumor spread in preclinical models 3 6 7 8 9 10. - Targeting multiple steps in the metastatic cascade, including cell migration and the tumor microenvironment, is a promising strategy 6 7 9. |
| What are the challenges and limitations in translating plant compounds to clinical practice? | - Issues such as poor solubility, bioavailability, and lack of standardized extraction methods limit clinical translation 3 5. - Variability in response and limited clinical trials highlight the need for more robust safety and efficacy data 2 3 5. |
How do plant-derived compounds affect cancer growth and cell death?
Related studies consistently show that various phytochemicals can inhibit cancer cell proliferation and survival by modulating multiple molecular pathways. The new DHL-11 study aligns with this body of evidence, demonstrating multi-pronged effects on TNBC cell growth, migration, and apoptosis.
- Phytochemicals suppress tumor growth through inhibition of key oncogenic pathways, such as JAK/STAT and PI3K/Akt, and by promoting cell cycle arrest and apoptosis 1 2 3 4 5.
- Plant-derived compounds can modulate gene and non-coding RNA expression, including miRNAs, to selectively target cancer cells 2 4.
- DHL-11’s mechanism—disrupting enzyme-protein interactions and degrading IMPDH2—adds to the variety of anti-cancer actions observed for plant compounds 2 4 5.
- The multi-targeted approach seen in DHL-11 is supported by related studies highlighting that effective phytochemicals often act on several pathways simultaneously 1 2 4 5.
Can plant-derived compounds inhibit metastasis and tumor progression?
There is growing evidence that plant-derived compounds can reduce not only tumor growth but also metastasis, a major challenge in cancer therapy. The DHL-11 study’s finding of reduced metastasis in TNBC models is consistent with this literature.
- Preclinical studies indicate that phytochemicals can inhibit key steps in the metastatic process, including cell migration, invasion, and colonization of distant organs 3 6 7 8 9 10.
- Targeting the tumor microenvironment and metastatic niche is an emerging strategy for improving outcomes in aggressive cancers 6 7 9.
- The anti-metastatic activity observed with DHL-11 supports the broader trend of plant compounds affecting both primary and metastatic tumors 3 8 10.
- Combination approaches that target multiple metastatic drivers, as seen with JAK2 and SMO inhibitors, are also being explored and show synergy in suppressing tumor spread 10.
What are the challenges and limitations in translating plant compounds to clinical practice?
Despite promising preclinical data, translation of plant-derived anti-cancer compounds to clinical use faces significant barriers. The DHL-11 study addresses some of these by using patient-derived organoids and animal models, but further work is needed.
- Poor solubility, limited bioavailability, and challenges in standardizing extraction and formulation hinder clinical application of many phytochemicals 3 5.
- Variability in patient response and the lack of large-scale clinical trials mean that many plant compounds have not yet reached routine clinical practice 2 3 5.
- Strategies such as nano-based formulations and chemical modifications are being investigated to improve delivery and reduce toxicity 5.
- The DHL-11 study’s demonstration of efficacy in advanced preclinical models is an important step toward addressing these translational challenges 3 5.
Future Research Questions
While DHL-11 shows promise as a targeted therapy for triple-negative breast cancer, several key questions remain. Further research is needed to address gaps in understanding, optimize delivery, and assess long-term safety and efficacy in clinical populations.
| Research Question | Relevance |
|---|---|
| What is the efficacy and safety of DHL-11 in clinical trials for triple-negative breast cancer? | Clinical trials are needed to confirm whether DHL-11’s preclinical efficacy and favorable biosafety profile translate to human patients, as most plant compounds have yet to be validated in large-scale studies 2 3 5. |
| How can the bioavailability and delivery of DHL-11 be optimized for therapeutic use? | Addressing formulation and delivery challenges is critical for translating DHL-11 from lab to clinic, as poor solubility and absorption are common barriers for plant-derived compounds 3 5. |
| Does DHL-11 have synergistic effects when combined with current breast cancer therapies? | Exploring potential synergies with standard treatments could enhance efficacy and overcome resistance, as seen with other combination therapies targeting multiple cancer pathways 10. |
| What are the molecular mechanisms underlying DHL-11’s selectivity for IMPDH2-positive tumors? | Understanding the basis for DHL-11’s selectivity could inform patient stratification and the development of companion diagnostics to identify those most likely to benefit 4 5. |
| Can DHL-11 be effective against other aggressive cancer types? | Investigating DHL-11’s effects in other cancers with high IMPDH2 expression or similar molecular profiles may broaden its therapeutic potential beyond TNBC 3 5. |